中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
1期
40-42
,共3页
罗克勇%刘克祥%王瑞超%付华斌
囉剋勇%劉剋祥%王瑞超%付華斌
라극용%류극상%왕서초%부화빈
痴呆%精神行为症状%阿立哌唑%利培酮
癡呆%精神行為癥狀%阿立哌唑%利培酮
치태%정신행위증상%아립고서%리배동
Dementia%Behavioral and psychological symptoms%Aripiprazole%Risperidone
目的 观察阿立哌唑和利培酮治疗老年痴呆精神行为症状的疗效及安全性.方法 采用随机对照研究,将具有精神行为症状的痴呆患者68例完全随机分为阿立哌唑组及利培酮组,各34例.阿立哌唑组患者服用阿立哌唑,起始剂量2.5 mg/d,最大剂量不超过15 mg/d;利培酮组患者口服利培酮,起始剂量0.5 mg/d,最大剂量不超过3 mg/d.疗程均为8周.治疗前和治疗第2、4、8周末采用痴呆病理分析评定量表(BEHAVE-AD)评定疗效,用副反应量表(TESS)评定不良反应,并于入组时和治疗第8周末分别检测2组患者空腹血糖、餐后2h血糖、TC、TG、LDL-C、HDL-C及体重.结果 阿立哌唑组和利培酮组患者治疗2、4、8周后BEHAVE-AD评分均明显低于治疗前[阿立哌唑组:(14.8±4.2)、(10.2±3.6)、(6.8±2.8)分比(16.4±4.6)分;利培酮组:(15.2±3.9)、(11.8±3.8)、(7.2±3.0)分比(17.2±5.0)分,P <0.05或P<0.01].2组患者间治疗前及治疗后BEHAVE-AD评分比较,差异均无统计学意义(P>0.05).2组不良反应发生率均为8.8% (3/34),差异无统计学意义(P>0.05).利培酮组治疗8周末体重较治疗前增加明显[(71±6)kg比(66±6) kg,P<0.05],TG及LDL-C升高[分别为(1.62±0.46) mmol/L比(0.96±0.29) mmol/L,(3.82±0.86) mmol/L比(3.08±0.74) mmol/L],而阿立哌唑组则改变不明显(均P>0.05).结论 阿立哌唑治疗老年痴呆精神行为症状总体疗效、安全性与利培酮相当,但阿立哌唑对患者血糖、血脂及体重影响小于利培酮.
目的 觀察阿立哌唑和利培酮治療老年癡呆精神行為癥狀的療效及安全性.方法 採用隨機對照研究,將具有精神行為癥狀的癡呆患者68例完全隨機分為阿立哌唑組及利培酮組,各34例.阿立哌唑組患者服用阿立哌唑,起始劑量2.5 mg/d,最大劑量不超過15 mg/d;利培酮組患者口服利培酮,起始劑量0.5 mg/d,最大劑量不超過3 mg/d.療程均為8週.治療前和治療第2、4、8週末採用癡呆病理分析評定量錶(BEHAVE-AD)評定療效,用副反應量錶(TESS)評定不良反應,併于入組時和治療第8週末分彆檢測2組患者空腹血糖、餐後2h血糖、TC、TG、LDL-C、HDL-C及體重.結果 阿立哌唑組和利培酮組患者治療2、4、8週後BEHAVE-AD評分均明顯低于治療前[阿立哌唑組:(14.8±4.2)、(10.2±3.6)、(6.8±2.8)分比(16.4±4.6)分;利培酮組:(15.2±3.9)、(11.8±3.8)、(7.2±3.0)分比(17.2±5.0)分,P <0.05或P<0.01].2組患者間治療前及治療後BEHAVE-AD評分比較,差異均無統計學意義(P>0.05).2組不良反應髮生率均為8.8% (3/34),差異無統計學意義(P>0.05).利培酮組治療8週末體重較治療前增加明顯[(71±6)kg比(66±6) kg,P<0.05],TG及LDL-C升高[分彆為(1.62±0.46) mmol/L比(0.96±0.29) mmol/L,(3.82±0.86) mmol/L比(3.08±0.74) mmol/L],而阿立哌唑組則改變不明顯(均P>0.05).結論 阿立哌唑治療老年癡呆精神行為癥狀總體療效、安全性與利培酮相噹,但阿立哌唑對患者血糖、血脂及體重影響小于利培酮.
목적 관찰아립고서화리배동치료노년치태정신행위증상적료효급안전성.방법 채용수궤대조연구,장구유정신행위증상적치태환자68례완전수궤분위아립고서조급리배동조,각34례.아립고서조환자복용아립고서,기시제량2.5 mg/d,최대제량불초과15 mg/d;리배동조환자구복리배동,기시제량0.5 mg/d,최대제량불초과3 mg/d.료정균위8주.치료전화치료제2、4、8주말채용치태병리분석평정량표(BEHAVE-AD)평정료효,용부반응량표(TESS)평정불량반응,병우입조시화치료제8주말분별검측2조환자공복혈당、찬후2h혈당、TC、TG、LDL-C、HDL-C급체중.결과 아립고서조화리배동조환자치료2、4、8주후BEHAVE-AD평분균명현저우치료전[아립고서조:(14.8±4.2)、(10.2±3.6)、(6.8±2.8)분비(16.4±4.6)분;리배동조:(15.2±3.9)、(11.8±3.8)、(7.2±3.0)분비(17.2±5.0)분,P <0.05혹P<0.01].2조환자간치료전급치료후BEHAVE-AD평분비교,차이균무통계학의의(P>0.05).2조불량반응발생솔균위8.8% (3/34),차이무통계학의의(P>0.05).리배동조치료8주말체중교치료전증가명현[(71±6)kg비(66±6) kg,P<0.05],TG급LDL-C승고[분별위(1.62±0.46) mmol/L비(0.96±0.29) mmol/L,(3.82±0.86) mmol/L비(3.08±0.74) mmol/L],이아립고서조칙개변불명현(균P>0.05).결론 아립고서치료노년치태정신행위증상총체료효、안전성여리배동상당,단아립고서대환자혈당、혈지급체중영향소우리배동.
Objective To assess the effect and safety of aripiprazole and risperidone in the treatment of behavioral and psychological symptoms of dementia (BPSD).Methods All 68 dementia were randomly divided into aripiprazole group (n =34) and risperidone group (n =34) with a course of 8 weeks.Aripiprazole was administered by patients in aripiprazole group with a starting dose of 2.5 mg/d and less than the maximum dose 15 mg/d,risperidone was administered by patients in risperidone group with a starting dose of 0.5 mg/d and less than the maximum dose 3 mg/d.Two groups were treated for 8 weeks.BEHAVE-AD and treatment emergent symptom scale (TESS) were used to evaluate the efficacy and adverse effect respectively before and at the ends of 8 weeks treatment.The levels of blood glucose,total cholesterol(TC),triglyceride(TG),high density lipoproteincholesterol (HDL-C),low density lipoprotein-cholesterol (LDL-C) and weight were measured at baseline and after 8 weeks.Results After 8 weeks treatment,the scores of BEHAVE-AD in both groups significantly reduced [aripiprazole group:(14.8 ± 4.2),(10.2 ± 3.6),(6.8 ± 2.6) scores vs (16.4 ± 4.6) scores ; risperidone group:(15.2 ±3.9),(11.8 ±3.8),(7.2 ±3.0)scores vs (17.2 ±5.0)scores,P<0.05 or P<0.01],but there were no significantly differences between the two groups (P > 0.05) ; there were few side effects in both groups [both 8.8% (3/34)],but the weight gaining,TC and LDL-C in risperidone group were higher than those before treatment [(71-±6)kg vs (66 ±6)kg,(1.62 ± 0.46) mmol/L vs (0.96 ± 0.29) mmol/L,(3.82±0.86)mmol/L vs (3.08 ± 0.74)mmol/L,all P < 0.05].Conclusion The results suggest that aripiprazole is as effective and safe as risperidone for the treatment of BPSD,but aripiprazole has less effect on blood glucose,lipids and weight than risperidone.